PF-Atlas › Clinical Trials › NCT07148739

Ensuring Access to Optimal Therapy in CF: The ENACT Study

Elexacaftor / Ivacaftor / Tezacaftor · Phase 4

Registry ID
NCT07148739
Phase
Phase 4
Status
Recruiting
Drug / intervention
Elexacaftor / Ivacaftor / Tezacaftor
Sponsor
Arkansas Children's Hospital Research Institute
Start
2025-06-10

About this trial

Elexacaftor / Ivacaftor / Tezacaftor is evaluated in NCT07148739, a Phase 4 idiopathic pulmonary fibrosis study sponsored by Arkansas Children's Hospital Research Institute. Current status: Recruiting.

View NCT07148739 on ClinicalTrials.gov →

Explore related

All Elexacaftor / Ivacaftor / Tezacaftor trialsAll IPF trials

Related trials

Elexacaftor / Ivacaftor / Tezacaftor — NCT05576324Elexacaftor / Ivacaftor / Tezacaftor — NCT05699148
Medical disclaimer. This page summarizes public trial data for NCT07148739 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.